Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 4/20 | 0.31 |
| ▸ | CASP8 | Q14790 | 3/20 | 0.31 |
| ▸ | CASP1 | P29466 | 2/20 | 0.31 |
| ▸ | CASP7 | P55210 | 2/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | XBP1 | P17861 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8520531 | 0.85 | CASP1 (0.47) | CTSSCASP3CASP8CASP1CTSK | |
| SCHEMBL7381224 | 0.73 | CASP3 (0.53) | CASP3CASP8CASP1CASP7CTSK | |
| SCHEMBL4422741 | 0.72 | CASP3 (0.49) | CTSSCASP3CASP8CASP1CASP7 | |
| SCHEMBL626800 | 0.72 | CASP3 (0.49) | CTSSCASP3CASP8CASP1CASP7 | |
| SCHEMBL10074125 | 0.72 | CASP3 (0.49) | CTSSCASP3CASP8CASP1CASP7 | |
| SCHEMBL6158897 | 0.71 | MMP9 (0.45) | CASP1CTSKMAPTXBP1NPSR1 | |
| SCHEMBL7428604 | 0.71 | MMP9 (0.45) | CASP1CTSKMAPTXBP1NPSR1 | |
| SCHEMBL7599891 | 0.70 | AKT1 (0.36) | CTSSAKT1USP2CASP3CASP8 | |
| SCHEMBL17261861 | 0.70 | CTSK (0.52) | CTSSCASP1CTSKCTSLCTSB | |
| SCHEMBL79538 | 0.69 | CASP1 (0.54) | CTSSCASP1CTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020156094-A1 | Sulfonamide interleukin-1beta converting enzyme inhibitors | WARNER-LAMBERT COMPANY | 2002-10-24 | — | — | US | disclosed |
| US-6316415-B1 | INHIBITORS OF INTERLEUKIN-1.BETA. CONVERTING ENZYME THAT HAVE THE TREATMENT OF STROKE, REPERFUSION INJURY, ALZHEIMER'S DISEASE, SHIGELLOSIS, INFLAMMATORY DISEASES, SEPTIC SHOCK AND TO AN INHIBITOR OF INTERLEUKIN-1.BETA. CONVERTING ENZYME. | BASF AKTIENGESELLSCHAFT (DE) | 2001-11-13 | — | — | US | disclosed |
| EP-0946502-A1 | SULFONAMIDE INTERLEUKIN-BETA CONVERTING ENZYME INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998016505-A1 | SULFONAMIDE INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156094-A1 | Sulfonamide interleukin-1beta converting enzyme inhibitors | IL1A, IL1B, IL1R1 | CTSS 148/4885AKT1 1416/4885USP2 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.